immunogen


Also found in: Thesaurus, Medical, Legal, Encyclopedia, Wikipedia.
Related to immunogen: hapten, Tolerogen

im·mu·no·gen

 (ĭ-myo͞o′nō-jən)
n.
An antigen that is capable of inducing an immune response.

[Formerly a trademark.]

immunogen

(ɪˈmjuːnəʊdʒən)
n
1. (Medicine) any substance that evokes an immune response
2. (Medicine) any substance that stimulates immunity

im•mu•no•gen

(ɪˈmyu nə dʒən, -ˌdʒɛn)

n.
any substance introduced into the body in order to generate an immune response.
[1955–60]
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.immunogen - any substance or organism that provokes an immune response (produces immunity) when introduced into the body
vaccine, vaccinum - immunogen consisting of a suspension of weakened or dead pathogenic cells injected in order to stimulate the production of antibodies
toxin antitoxin - a mixture of toxin and antitoxin used to immunize against a disease
antigen - any substance (as a toxin or enzyme) that stimulates an immune response in the body (especially the production of antibodies)
Translations

im·mu·no·gen

n. inmunógeno, sustancia que produce inmunidad;
targeted ______ específico.
References in periodicals archive ?
ImmunoGen helps fund its programs by licensing its TAP technology to other companies.
Roche is developing this compound globally under an agreement between ImmunoGen and Genentech, a member of the Roche Group.
The presentation is scheduled for 8:00 am PT on January 7, 2013 and will include information about IMGN289, which is on track to become the fourth wholly owned ImmunoGen compound to advance into clinical testing.
Pursuant to the agreement, ImmunoGen received $2 million upon confirmation of ImmunoGen's capability to produce sufficient quantities of huC242-DM1 in advance of the start of clinical trials for the product.
Mitchel Sayare, ImmunoGen Chairman and Chief Executive Officer, states that "In his new position, Dr.
Roche is developing this compound under an agreement between ImmunoGen and Genentech, a member of the Roche Group.
In preclinical studies, mice were given B-cell tumors which are resistant to the effects of conventional anti-cancer drugs," explains Walter Blattler, ImmunoGen Vice President, Research.
During his tenure with ImmunoGen, Don played a major role in the development of our commercialization strategy," said Mitchel Sayare, ImmunoGen chairman and chief executive officer.
With the development of resurfacing, ImmunoGen has in hand an effective proprietary method of humanization which can be used with any monoclonal antibodies," states Chairman and Chief Executive Officer, Mitchel Sayare.